Phaseline

Targets › ERAP1

ERAP1 (Endoplasmic reticulum aminopeptidase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Apr 2028.

Aminopeptidase that plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides. Peptide trimming is essential to customize longer precursor peptides to fit them to the correct length required for presentation on MHC class I molecules. (UniProt, Q9NZ08)

Open in Phaseline: the race on ERAP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Grey Wolf TherapeuticsGRWD0715
Selective ERAP1 inhibitor
ERAP1Phase 1Axial Spondyloarthritis (AxSpA)Apr 2028

Conditions

Axial Spondyloarthritis (AxSpA) (1)

Modalities

small molecule (1)

Companies

Grey Wolf Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.